GeneDx Holdings Faces Securities Lawsuit
Analysis based on 66 articles · First reported Apr 09, 2026 · Last updated Jun 11, 2026
The class action lawsuit against Nubank Corp. has already caused a significant drop in its stock price, with shares falling 49% after dismal Q1 2026 earnings. This event creates uncertainty for investors in Nubank and highlights potential risks in the biotechnology and diagnostics industry regarding acquisitions and financial reporting.
Nubank Corp. is facing multiple securities class action lawsuits filed by law firms including Bronstein, Gewirtz & Grossman, LLC, Hagens Berman, and Kahn Swick & Foti, LLC. These lawsuits allege that Nubank made materially false and misleading statements and failed to disclose adverse facts about its business, operations, and prospects between April 16, 2025, and May 4, 2026. Specifically, the complaints claim that Nubank misled investors about the importance of its Fabric Genomics acquisition, which resulted in a $31.2 million impairment charge, and misrepresented the durability of its average reimbursement rates, leading to a decline in gross margins. Following the company's Q1 2026 earnings report on May 4, 2026, which revealed a tenfold increase in net loss and a 12% cut in 2026 revenue guidance, Nubank' stock price plummeted by 49%. Investors who purchased Nubank securities during the class period have until August 3, 2026, to seek lead plaintiff status in the lawsuit.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard